{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:55Z","timestamp":1786988035232,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013119","name":"PharmaMar SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.06.020","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T17:34:24Z","timestamp":1657560864000},"page":"357-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-7902","authenticated-orcid":false,"given":"Daphne W.","family":"Dumoulin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-4758","authenticated-orcid":false,"given":"Luca","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3092","authenticated-orcid":false,"given":"Robin","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelief","family":"Vink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Klaase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kick","family":"Slooff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nura","family":"Tebayna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3653-9043","authenticated-orcid":false,"given":"Joanne M.","family":"Mankor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1427-901X","authenticated-orcid":false,"given":"Sara J.","family":"Baart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3376-6734","authenticated-orcid":false,"given":"Marcella","family":"Willemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6662-2951","authenticated-orcid":false,"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.06.020_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.06.020_bib2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup Analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2022.06.020_bib3","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.21037\/tlcr-19-686","article-title":"Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program","volume":"9","author":"Cantini","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2022.06.020_bib4","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.21037\/tlcr-20-630","article-title":"Immunotherapy in small cell lung cancer: one step at a time: a narrative review","volume":"10","author":"Dumoulin","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2022.06.020_bib5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging treatments for malignant pleural mesothelioma: where are we heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.06.020_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.06.020_bib7","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2217\/fon-2020-1212","article-title":"Lurbinectedin in the treatment of relapsed small cell lung cancer","volume":"17","author":"Baena","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2022.06.020_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.annonc.2019.12.009","article-title":"Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17\/16)","volume":"31","author":"Metaxas","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2022.06.020_bib9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/1541-7786.MCR-18-0575","article-title":"The antitumor drugs trabectedin and lurbinectedin induce transcription-dependent replication stress and genome instability","volume":"17","author":"Tumini","year":"2019","journal-title":"Mol Cancer Res MCR"},{"key":"10.1016\/j.ejca.2022.06.020_bib10","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1158\/0008-5472.CAN-16-0568","article-title":"Lurbinectedin inactivates the ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus","volume":"76","author":"Harlow","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.06.020_bib11","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells","volume":"15","author":"Santamar\u00eda Nu\u00f1ez","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2022.06.020_bib12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.06.020_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1158\/2326-6066.CIR-16-0309","article-title":"Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy","volume":"5","author":"Dammeijer","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2022.06.020_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100446","article-title":"Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17\/16 study","volume":"7","author":"Mark","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.06.020_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/srep15437","article-title":"Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients","volume":"5","author":"Horita","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2022.06.020_bib16","unstructured":"No Overall Survival Benefit With Lurbinectedin\/Doxorubicin in Small Cell Lung Cancer - The ASCO Post n.d. https:\/\/ascopost.com\/news\/september-2021\/no-overall-survival-benefit-with-lurbinectedindoxorubicin-in-small-cell-lung-cancer\/ (accessed December 3, 2021)."},{"key":"10.1016\/j.ejca.2022.06.020_bib17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00262-020-02513-y","article-title":"Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia","volume":"69","author":"Risnik","year":"2020","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.ejca.2022.06.020_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1656502","article-title":"Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity","volume":"8","author":"Xie","year":"2019","journal-title":"OncoImmunology"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:50Z","timestamp":1760733530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":18,"alternative-id":["S0959804922003719"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}